|
考量項目 治療選項 |
||
|---|---|---|
| 介白素-23拮抗劑(anti-IL-23) | Risankizumab(Skyrizi®，喜開悅®) | |
| Guselkumab(Tremfya®，特諾雅®) | ||
| 介白素-12/23抑制劑(anti-IL-12/23) | Ustekinumab(Stelara®，喜達諾®) | |
| 介⽩素-17拮抗劑/抗體(anti-IL-17) | IL-17A | Secukinumab(Cosentyx®，可善挺®) |
| IL-17A | Ixckizumab(Taltz®，達癬治®) | |
| IL-17RA | Brodalumab(Lumicet®，⽴美西膚®) | |
| IL-17A/F | Bimekizumab(Bimzelx®，本能適®) | |
| 腫瘤壞死因子 抑制劑anti-TNF-ɑ | Etanercept(如：Enbrel®，恩博®) | |
| Adalimumab(如：Humira®，復邁®) | ||
| Certolizumab pegol(Cimzia®，欣膝亞®) | ||